Unknown

Dataset Information

0

The Novel Atypical Dopamine Uptake Inhibitor (S)-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding.


ABSTRACT: Animal studies of effort-based choice behavior are being used to model effort-related motivational dysfunctions in humans. With these procedures, animals are offered a choice between high-effort instrumental actions leading to highly valued reinforcers vs. low effort/low reward options. Several previous studies have shown that dopamine (DA) uptake inhibitors, including GBR12909, lisdexamfetamine, methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular monoamine transport blocker tetrabenazine, which inhibits DA storage. Because many drugs that block DA transport act as major stimulants that also release DA, and produce a number of undesirable side effects, there is a need to develop and characterize novel atypical DA transport inhibitors. (S)-CE-123 ((S)-5-((benzhydrylsulfinyl) methyl)thiazole) is a recently developed analog of modafinil with the biochemical characteristics of an atypical DA transport blocker. The present paper describes the enantioselective synthesis and initial chemical characterization of (S)-CE-123, as well as behavioral experiments involving effort-based choice and microdialysis studies of extracellular DA. Rats were assessed using the fixed ratio 5/chow feeding choice test. Tetrabenazine (1.0 mg/kg) shifted choice behavior, decreasing lever pressing and increasing chow intake. (S)-CE-123 was coadministered at doses ranging from 6.0 to 24.0 mg/kg, and the highest dose partially but significantly reversed the effects of tetrabenazine, although this dose had no effect on fixed ratio responding when administered alone. Additional experiments showed that (S)-CE-123 significantly increased lever pressing on a progressive ratio/chow feeding choice task and that the effective dose (24.0 mg/kg) increased extracellular DA in nucleus accumbens core. In summary, (S)-CE-123 has the behavioral and neurochemical profile of a compound that can block DA transport, reverse the effort-related effects of tetrabenazine, and increase selection of high-effort progressive ratio responding. This suggests that (S)-CE-123 or a similar compound could be useful as a treatment for effort-related motivational dysfunction in humans.

SUBMITTER: Rotolo RA 

PROVIDER: S-EPMC6611521 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Novel Atypical Dopamine Uptake Inhibitor <i>(S)</i>-CE-123 Partially Reverses the Effort-Related Effects of the Dopamine Depleting Agent Tetrabenazine and Increases Progressive Ratio Responding.

Rotolo Renee A RA   Dragacevic Vladimir V   Kalaba Predrag P   Urban Ernst E   Zehl Martin M   Roller Alexander A   Wackerlig Judith J   Langer Thierry T   Pistis Marco M   De Luca Maria Antonietta MA   Caria Francesca F   Schwartz Rebecca R   Presby Rose E RE   Yang Jen-Hau JH   Samels Shanna S   Correa Merce M   Lubec Gert G   Salamone John D JD  

Frontiers in pharmacology 20190628


Animal studies of effort-based choice behavior are being used to model effort-related motivational dysfunctions in humans. With these procedures, animals are offered a choice between high-effort instrumental actions leading to highly valued reinforcers vs. low effort/low reward options. Several previous studies have shown that dopamine (DA) uptake inhibitors, including GBR12909, lisdexamfetamine, methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular monoamine tr  ...[more]

Similar Datasets

| S-EPMC5711856 | biostudies-literature
| S-EPMC7047258 | biostudies-literature
| S-EPMC8671572 | biostudies-literature
| S-EPMC3030450 | biostudies-literature
| S-EPMC8789874 | biostudies-literature
2022-02-16 | PXD022737 | Pride
| S-EPMC4734652 | biostudies-literature
| S-EPMC8152852 | biostudies-literature
| S-EPMC4784967 | biostudies-literature
| S-EPMC2907444 | biostudies-literature